Generic placeholder image

Drug Metabolism Letters

Author(s): Sarvesh Sabarathinam* and Thangavel M. Vijayakumar*

DOI: 10.2174/1872312814666201112122110

Cite As
Assessment of Herb-drug Interactions Based on the Pharmacokinetic Changes of Probe Drug, Midazolam

Page: [5 - 8] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Background: In healthy volunteers, the probe drug method is widely practised to assess the pharmacokinetic mediated herb-drug interactions (HDI). We analyzed the clinical evidence of CYP3 A4 probe drug, Midazolam.

Methods: Literatures, where Midazolam was used as a probe drug for prediction of herb-drug interaction, were surveyed through an online database such as google scholar, Scopus, Cochrane, PubMed and clinicaltrials.gov.

Results: Midazolam was considered a sensitive probe for CYP3A4 substrates due to its bioavailability. We observed that not all the herbs are causing drug interaction. However, significant changes of the Midazolam pharmacokinetics were found after high-dose and long-term intake of some herbs and food supplements, suggesting the induction and/or inhibition of CYP activities.

Conclusion: Probe drug technique is one of the easiest ways for predicting CYP enzyme-mediated herb-drug interactions. Midazolam shows a good response in clinical studies because of short halflife and low harmfulness compared with other probe drugs.

Keywords: CYP3A4, herb-drug interactions, healthy volunteers, midazolam, metabolism, pharmacokinetics, probe drug, substrates.

[1]
Ekor, M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol., 2014, 4(177), 177.
[http://dx.doi.org/10.3389/fphar.2013.00177] [PMID: 24454289]
[2]
Jermini, M.; Dubois, J.; Rodondi, P.Y.; Zaman, K.; Buclin, T.; Csajka, C.; Orcurto, A.; E Rothuizen, L. Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. Sci. Rep., 2019, 9(1), 5078.
[http://dx.doi.org/10.1038/s41598-019-41532-3] [PMID: 30911084]
[3]
Shrilatha, K. Prevalence and pattern of use of complementary and alternative medicine in diabetes patients in a south Indian tertiary care teaching hospital. Drug Invent. Today, 2019, 11(2), 274-279.
[4]
Sarvesh, S.; Koushik Muthu Raja, M.; Rajanandh, M.G.; Seenivasan, P. Prevalence and pattern of usage of complementary and alternative medicine among south Indian asthma patients in a tertiary care hospital. Complement. Ther. Clin. Pract., 2018, 30(30), 103-108.
[http://dx.doi.org/10.1016/j.ctcp.2017.12.016] [PMID: 29389468]
[5]
Mohd Nor, N.H.; Othman, F.; Mohd Tohit, E.R.; Md Noor, S. Medicinal herbals with antiplatelet properties benefit in coronary atherothrombotic diseases. Thrombosis, 2016, 2016, 5952910.
[http://dx.doi.org/10.1155/2016/5952910] [PMID: 27051529]
[6]
Choi, S.; Oh, D-S.; Jerng, U.M. A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin. PLoS One, 2017, 12(8), e0182794.
[http://dx.doi.org/10.1371/journal.pone.0182794] [PMID: 28797065]
[7]
Borse, S.P.; Singh, D.P.; Nivsarkar, M. Understanding the relevance of herb-drug interaction studies with special focus on interplays: a prerequisite for integrative medicine. Porto. Biomed. J., 2019, 4(2), e15.
[http://dx.doi.org/10.1016/j.pbj.0000000000000015] [PMID: 31595257]
[8]
Wanwimolruk, S.; Prachayasittikul, V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). EXCLI J. , 2014, 13 , 347 -391 .
[9]
Na, D.H.; Ji, H.Y.; Park, E.J.; Kim, M.S.; Liu, K-H.; Lee, H.S. Evaluation of metabolism-mediated herb-drug interactions. Arch. Pharm. Res., 2011, 34(11), 1829-1842.
[http://dx.doi.org/10.1007/s12272-011-1105-0] [PMID: 22139684]
[10]
Halama, B.; Hohmann, N.; Burhenne, J.; Weiss, J.; Mikus, G.; Haefeli, W.E. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin. Pharmacol. Ther., 2013, 93(6), 564-571.
[http://dx.doi.org/10.1038/clpt.2013.27] [PMID: 23511711]
[11]
Veronese, M.L.; Gillen, L.P.; Burke, J.P.; Dorval, E.P.; Hauck, W.W.; Pequignot, E.; Waldman, S.A.; Greenberg, H.E. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J. Clin. Pharmacol., 2003, 43(8), 831-839.
[http://dx.doi.org/10.1177/0091270003256059] [PMID: 12953340]
[12]
Uchida, S.; Yamada, H.; Li, X.D.; Maruyama, S.; Ohmori, Y.; Oki, T.; Watanabe, H.; Umegaki, K.; Ohashi, K.; Yamada, S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J. Clin. Pharmacol., 2006, 46(11), 1290-1298.
[http://dx.doi.org/10.1177/0091270006292628] [PMID: 17050793]
[13]
Robertson, S.M.; Davey, R.T.; Voell, J.; Formentini, E.; Alfaro, R.M.; Penzak, S.R. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr. Med. Res. Opin., 2008, 24(2), 591-599.
[http://dx.doi.org/10.1185/030079908X260871] [PMID: 18205997]
[14]
Abdelkawy, K.S.; Donia, A.; Abdallah, M. Pharmacokinetics interaction of dapoxetine with different doses of green tea extract in male healthy volunteers using Midazolam as CYP3A4 enzyme probe. J. App. Pharm. Sci., 2015, 5 , 001 -007 .
[15]
Farkas, D.; Oleson, L.E.; Zhao, Y.; Harmatz, J.S.; Zinny, M.A.; Court, M.H.; Greenblatt, D.J. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J. Clin. Pharmacol., 2007, 47(3), 286-294.
[http://dx.doi.org/10.1177/0091270006298359] [PMID: 17322140]
[16]
Chen, Y.; Ouyang, D-S.; Kang, Z.; Yang, G-P.; Tan, Z-R.; Zhou, G.; Yan, J. Effect of a traditional Chinese medicine Liu Wei Di Huang Wan on the activities of CYP2C19, CYP2D6 and CYP3A4 in healthy volunteers. Xenobiotica, 2012, 42(6), 596-602.
[http://dx.doi.org/10.3109/00498254.2011.644596] [PMID: 22208477]
[17]
Lilja, J.J.; Backman, J.T.; Neuvonen, P.J. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. Clin. Pharmacol. Ther., 2007, 81(6), 833-839.
[http://dx.doi.org/10.1038/sj.clpt.6100149] [PMID: 17392729]
[18]
Tu, J-H.; He, Y-J.; Chen, Y.; Fan, L.; Zhang, W.; Tan, Z-R.; Huang, Y.F.; Guo, D.; Hu, D.L.; Wang, D.; Hong-Hao Zhou, Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur. J. Clin. Pharmacol., 2010, 66(8), 805-810.
[http://dx.doi.org/10.1007/s00228-010-0814-5] [PMID: 20393696]
[19]
Wongnawa, M. The effects of Andrographis paniculata (Burm.f.) Nees on the pharmacokinetics and pharmacodynamics of Midazolam in healthy volunteers. Songklanakarin J. Sci. Technol., 2012, 34, 533-539.
[20]
Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Cui, Y.; Ang, C.Y.W. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther., 2002, 72(3), 276-287.
[http://dx.doi.org/10.1067/mcp.2002.126913] [PMID: 12235448]
[21]
Doroshyenko, O.; Rokitta, D.; Zadoyan, G.; Klement, S.; Schläfke, S.; Dienel, A.; Gramatté, T.; Lück, H.; Fuhr, U. Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab. Dispos., 2013, 41(5), 987-993.
[http://dx.doi.org/10.1124/dmd.112.050203] [PMID: 23401474]
[22]
Malati, C.Y.; Robertson, S.M.; Hunt, J.D.; Chairez, C.; Alfaro, R.M.; Kovacs, J.A.; Penzak, S.R. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J. Clin. Pharmacol., 2012, 52(6), 932-939.
[http://dx.doi.org/10.1177/0091270011407194] [PMID: 21646440]
[23]
Teo, Y.L.; Ho, H.K.; Chan, A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br. J. Clin. Pharmacol., 2015, 79(2), 241-253.
[http://dx.doi.org/10.1111/bcp.12496] [PMID: 25125025]
[24]
Fisher, C.D.; Lickteig, A.J.; Augustine, L.M.; Ranger-Moore, J.; Jackson, J.P.; Ferguson, S.S.; Cherrington, N.J. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab. Dispos., 2009, 37(10), 2087-2094.
[http://dx.doi.org/10.1124/dmd.109.027466] [PMID: 19651758]
[25]
Hu, S.X.; Mazur, C.A.; Feenstra, K.L. Assessment of inhibition of bovine hepatic cytochrome P450 by 43 commercial bovine medicines using a combination of in vitro assays and pharmacokinetic data from the literature. Drug Metab. Lett., 2019, 13(2), 123-131.
[http://dx.doi.org/10.2174/1872312813666191120094649] [PMID: 31750810]
[26]
Sarvesh Sabarathinam, T.M. Vijayakumar. RP-HPLC Method Development and Validation of Midazolam: A CYP3A4 Probe Drug. Res. J. Pharm. and Tech, 2020, 13(8), 3565-3568.
[http://dx.doi.org/10.5958/0974-360X.2020.00630.7]
[27]
Sabarathinam, S.; Vijayakumar, T.M. A short exploration of selected sensitive CYP3A4 substrates (Probe Drug). Drug Metab. Lett., 2020, 14, 1.
[http://dx.doi.org/10.2174/1872312814666200811110024] [PMID: 32781977]